Published in Medical Letter on the CDC and FDA, July 24th, 2005
The company is currently reviewing the U.S. Food and Drug Administration's (FDA) response and will meet with the agency over the next few weeks to address the outstanding issues.
Organon is confident that it will be able to provide the FDA with the appropriate information to expedite their review.
Organon, with shared head offices in Roseland, Jersey, USA and Oss, The Netherlands, creates manufactures and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.